Keith Flaherty, MD, FAACR, discusses the 2026 AACR Cancer Progress Report and how the oncology field can build on the report’s findings.
News|Articles|September 4, 2026
- Vol.27/No.10
- Volume 27
- Issue 10
Brachytherapy and Minimally Invasive Surgical Techniques Signal the Future of Brain Cancer Management
Author(s)Ashling Wahner
Fact checked by: Riley Kandel, Cheney Gazzam Baltz
Brain cancer experts explain the current wave of surgical advances and advocate for team-based, multidisciplinary strategies to individualize patient care.
Advertisement
Advertisement
A wave of minimally invasive surgical methods and implantable radiation technology is revolutionizing brain cancer care, with experts emphasizing that these modalities complement, rather than replace, traditional methods and require multidisciplinary, patient-specific decision-making.
Related to this article
NEXERA-303 is evaluating INCA33890 plus FOLFOX and bevacizumab vs chemotherapy and bevacizumab alone in previously untreated MSS mCRC.
Community hematologists/oncologists discussed bispecific antibody integration in community practice for relapsed/refractory multiple myeloma.
TP53 Comutations, Long-Term Toxicity, and Sunvozertinib Access Shape EGFR+ NSCLC Treatment Decisions
Faculty at an OncLive Scientific Interchange and Workshop discussed factors that help inform treatment selection in advanced EGFR-mutated NSCLC.
Faculty at an OncLive Scientific Interchange and Workshop discussed operationalizing outpatient bispecific antibody therapy for relapsed/refractory multiple myeloma.
RELATIVITY-1093 is comparing nivolumab and relatlimab plus chemotherapy vs pembrolizumab plus chemotherapy in PD-L1–positive nonsquamous NSCLC.
P. Leia Nghiemphu, MD, discusses INTUITT-NF2 trial findings, the NCCN inclusion of brigatinib, and unmet needs in NF2-related schwannomatosis.
Biagio Ricciuti, MD, PhD, discusses Krascendo 1 data for divarasib, co-mutation–guided sequencing, and emerging RAS inhibitors in KRAS G12C–positive NSCLC.
Advertisement
Advertisement